• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于生物医学应用的红细胞膜处理

Red Blood Cell Membrane Processing for Biomedical Applications.

作者信息

Rossi Luigia, Fraternale Alessandra, Bianchi Marzia, Magnani Mauro

机构信息

Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.

EryDel SpA, Bresso, Italy.

出版信息

Front Physiol. 2019 Aug 20;10:1070. doi: 10.3389/fphys.2019.01070. eCollection 2019.

DOI:10.3389/fphys.2019.01070
PMID:31481901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6710399/
Abstract

Red blood cells (RBC) are actually exploited as innovative drug delivery systems with unconventional and convenient properties. Because of a long survival and a non-random removal from circulation, RBC can be loaded with drugs and/or contrasting agents without affecting these properties and maintaining the original immune competence. However, native or drug-loaded RBC, can be modified decorating the membrane with peptides, antibodies or small chemical entities so favoring the targeting of the processed RBC to specific cells or organs. Convenient modifications have been exploited to induce immune tolerance or immunogenicity, to deliver antibodies capable of targeting other cells, and to deliver a number of constructs that can recognize circulating pathogens or toxins. The methods used to induce membrane processing useful for biomedical applications include the use of crosslinking agents and bifunctional antibodies, biotinylation and membrane insertion. Another approach includes the expression of engineered membrane proteins upon transfection of immature erythroid precursors with lentiviral vectors, followed by expansion and differentiation into mature erythrocytes before administration to a patient in need. Several applications have now reached the clinic and a couple of companies that take advantage from these properties of RBC are already in Phase 3 with selected applications. The peculiar properties of the RBC and the active research in this field by a number of qualified investigators, have opened new exciting perspectives on the use of RBC as carriers of drugs or as cellular therapeutics.

摘要

红细胞(RBC)实际上被用作具有非常规且便利特性的创新药物递送系统。由于其生存期长且从循环中被非随机清除,红细胞可以装载药物和/或造影剂,而不会影响这些特性并保持原始免疫能力。然而,天然或载药红细胞可以通过用肽、抗体或小化学实体修饰膜来进行改造,从而有利于将处理后的红细胞靶向特定细胞或器官。已经利用了便利的修饰来诱导免疫耐受或免疫原性,递送能够靶向其他细胞的抗体,并递送许多能够识别循环病原体或毒素的构建体。用于诱导对生物医学应用有用的膜处理的方法包括使用交联剂和双功能抗体、生物素化和膜插入。另一种方法包括在用慢病毒载体转染未成熟红细胞前体后表达工程化膜蛋白,然后在给予有需要的患者之前将其扩增并分化为成熟红细胞。现在有几种应用已经进入临床,并且有几家利用红细胞这些特性的公司在选定的应用方面已经进入了三期临床试验。红细胞的独特特性以及许多合格研究人员在该领域的积极研究,为将红细胞用作药物载体或细胞疗法开辟了新的令人兴奋的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c24f/6710399/2944711c9b99/fphys-10-01070-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c24f/6710399/2944711c9b99/fphys-10-01070-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c24f/6710399/2944711c9b99/fphys-10-01070-g001.jpg

相似文献

1
Red Blood Cell Membrane Processing for Biomedical Applications.用于生物医学应用的红细胞膜处理
Front Physiol. 2019 Aug 20;10:1070. doi: 10.3389/fphys.2019.01070. eCollection 2019.
2
Erythrocytes as Carriers for Drugs and Contrast Agents.红细胞作为药物和造影剂的载体。
Cent Asian J Glob Health. 2014 Jan 24;2(Suppl):89. doi: 10.5195/cajgh.2013.89. eCollection 2013.
3
Drug delivery by red blood cells: vascular carriers designed by mother nature.红细胞介导的药物递送:源于大自然的血管载体。
Expert Opin Drug Deliv. 2010 Apr;7(4):403-27. doi: 10.1517/17425241003610633.
4
Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats.抗体与生物素化红细胞的结合:免疫红细胞对固定化抗原显示出高亲和力,并在大鼠体内具有正常的生物分布。
Biotechnol Appl Biochem. 1996 Aug;24(1):41-5.
5
Red Blood Cells as Smart Delivery Systems.红细胞作为智能递药系统。
Bioconjug Chem. 2018 Apr 18;29(4):852-860. doi: 10.1021/acs.bioconjchem.7b00758. Epub 2018 Jan 22.
6
Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs.免疫亲和素负载红细胞作为一种新的免疫抑制药物传递策略。
J Control Release. 2011 Sep 25;154(3):306-13. doi: 10.1016/j.jconrel.2011.05.024. Epub 2011 May 27.
7
Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin.补体介导的生物素和链霉亲和素修饰红细胞清除的调控
Anal Biochem. 1996 Oct 1;241(1):109-19. doi: 10.1006/abio.1996.0384.
8
Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors.红细胞-癌细胞杂化膜伪装黑色素纳米颗粒增强肿瘤光热治疗效果。
Biomaterials. 2019 Feb;192:292-308. doi: 10.1016/j.biomaterials.2018.11.021. Epub 2018 Nov 15.
9
Drug delivery by erythrocytes: "Primum non nocere".红细胞介导的药物递送:“首要原则是不伤害” 。
Transfus Apher Sci. 2016 Dec;55(3):275-280. doi: 10.1016/j.transci.2016.10.017. Epub 2016 Oct 31.
10
Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.红细胞:药物、生物制剂和纳米颗粒的超级载体以及先进递送系统的灵感来源。
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):88-103. doi: 10.1016/j.addr.2016.02.007. Epub 2016 Mar 3.

引用本文的文献

1
Red blood cells could protect miRNAs from degradation or loss thanks to Argonaute 2 binding.由于与AGO2蛋白结合,红细胞可以保护微小RNA不被降解或丢失。
FEBS Open Bio. 2025 May;15(5):810-821. doi: 10.1002/2211-5463.70005. Epub 2025 Apr 15.
2
Harnessing the potential of red blood cells in immunotherapy.挖掘红细胞在免疫治疗中的潜力。
Hum Immunol. 2024 Nov;85(6):111084. doi: 10.1016/j.humimm.2024.111084. Epub 2024 Sep 9.
3
Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules.

本文引用的文献

1
Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude.红细胞“搭便车”可将纳米载体递送至目标器官,效率提高数个数量级。
Nat Commun. 2018 Jul 11;9(1):2684. doi: 10.1038/s41467-018-05079-7.
2
Biocompatible coupling of therapeutic fusion proteins to human erythrocytes.治疗性融合蛋白与人红细胞的生物相容性偶联。
Blood Adv. 2018 Feb 13;2(3):165-176. doi: 10.1182/bloodadvances.2017011734.
3
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.
高效且高度可重现的红细胞衍生细胞外囊泡模拟物的生产,用于 RNA 分子的加载和递送。
Sci Rep. 2024 Jun 25;14(1):14610. doi: 10.1038/s41598-024-65623-y.
4
Mechanism of hypoxia-induced damage to the mechanical property in human erythrocytes-band 3 phosphorylation and sulfhydryl oxidation of membrane proteins.缺氧诱导人红细胞机械性能损伤的机制——膜蛋白带3磷酸化和巯基氧化
Front Physiol. 2024 Apr 19;15:1399154. doi: 10.3389/fphys.2024.1399154. eCollection 2024.
5
Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications.用于癌症治疗的红细胞衍生材料:构建、分布及应用
Mater Today Bio. 2023 Dec 15;24:100913. doi: 10.1016/j.mtbio.2023.100913. eCollection 2024 Feb.
6
Drug transport by red blood cells.红细胞的药物转运
Front Physiol. 2023 Dec 11;14:1308632. doi: 10.3389/fphys.2023.1308632. eCollection 2023.
7
Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs.细胞外囊泡作为药物递送的新参与者:聚焦于红细胞衍生的细胞外囊泡
Pharmaceutics. 2023 Jan 21;15(2):365. doi: 10.3390/pharmaceutics15020365.
8
The Effect of Selected Flavonoids and Lipoic Acid on Natural and Model Cell Membranes: Langmuir and Microelectrophoretic Methods.某些类黄酮和硫辛酸对天然和模型细胞膜的影响:Langmuir 和微电泳方法。
Molecules. 2023 Jan 19;28(3):1013. doi: 10.3390/molecules28031013.
9
Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies.通过新型抗带 3 单域抗体的红细胞搭便车延长生物治疗半衰期和调节生物分布。
Int J Mol Sci. 2022 Dec 28;24(1):475. doi: 10.3390/ijms24010475.
10
Surface Modification of Erythrocytes with Lipid Anchors: Structure-Activity Relationship for Optimal Membrane Incorporation, in vivo Retention, and Immunocompatibility.脂质锚定修饰红细胞:最佳膜整合、体内保留及免疫相容性的构效关系
Adv Nanobiomed Res. 2022 Aug;2(8). doi: 10.1002/anbr.202200037. Epub 2022 Jul 19.
表达单域骆驼科抗体的基因工程红细胞可提供针对肉毒杆菌神经毒素的长期保护。
Nat Commun. 2017 Sep 4;8(1):423. doi: 10.1038/s41467-017-00448-0.
4
Bioengineering strategies for inducing tolerance in autoimmune diabetes.诱导自身免疫性糖尿病耐受的生物工程策略。
Adv Drug Deliv Rev. 2017 May 15;114:256-265. doi: 10.1016/j.addr.2017.06.007. Epub 2017 Jun 15.
5
Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.与抗原肽共价连接的工程红细胞可预防自身免疫性疾病。
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3157-3162. doi: 10.1073/pnas.1701746114. Epub 2017 Mar 7.
6
Reengineering red blood cells for cellular therapeutics and diagnostics.为细胞治疗和诊断对红细胞进行重新设计。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5). doi: 10.1002/wnan.1454. Epub 2017 Jan 24.
7
Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment.使用全自动生物医学设备将地塞米松磷酸钠进行体外包封至人自体红细胞中。
Int J Pharm. 2017 Jan 30;517(1-2):175-184. doi: 10.1016/j.ijpharm.2016.12.011. Epub 2016 Dec 7.
8
Understanding red blood cell alloimmunization triggers.了解红细胞同种免疫的触发因素。
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):446-451. doi: 10.1182/asheducation-2016.1.446.
9
Engineering erythrocytes for the modulation of drugs' and contrasting agents' pharmacokinetics and biodistribution.工程化红细胞用于调控药物和对比剂的药代动力学和生物分布。
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):73-87. doi: 10.1016/j.addr.2016.05.008. Epub 2016 May 14.
10
Erythrocyte-mediated delivery of recombinant enzymes.红细胞介导的重组酶递送。
J Inherit Metab Dis. 2016 Jul;39(4):519-30. doi: 10.1007/s10545-016-9926-0. Epub 2016 Mar 30.